Abstract 5066
Background
Receiving a diagnosis of cancer may be associated with increased psychosocial distress. Without objective assessments, healthcare professionals tend to underestimate psychological distress, and fail in the recognition, triage and referral of distressed patients. The specific aims of this study are to identify the level and the nature of the distress.
Methods
A descriptive prospective design has been used to analyze the data of distress thermometer (DT) in initial visits in the cancer unit. Data collection was conducted by nurses over a six month period. The variables studied were: age, sex, type of tumor, intensity and causes of distress.
Results
39 patients answered the DT screening tool. On average, the participants were 58.1 years old and 64% of them were female. The most frequent diagnoses reported were breast cancer (38%) and colon cancer (26%). 41 % rated over the cut point of DT (>4) and were referred to psycho-oncology attention. Only the 48 % attended to the psychologist after referral despite the most frequent causes of distress were physical problems (85%) and emotional problems (70%). Finally, there were a statistically significant association between intensity of distress and emotional problems (r = 0,648; p < 0, 001) but not with other problematic areas (physical, family, spiritual or practical).
Conclusions
Psychosocial distress in recently diagnosed cancer patients seems to be related with emotional problems. It is important to evaluate and manage emotional distress in these patients to improve their quality of life and refer patients to the psychologist when it is necessary.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
E Bailles.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2600 - Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): a long-term overall survival (OS) and safety update from the Phase III IMvigor211 study
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3598 - Three-Year Follow-Up From the Phase 3 KEYNOTE-045 Trial: Pembrolizumab (Pembro) Versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer (UC)
Presenter: Andrea Necchi
Session: Poster Display session 3
Resources:
Abstract
2382 - First Report of Efficacy and Safety From a Phase 2 Trial of Tislelizumab, an Anti-PD-1 Antibody, for the Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma (UC) in Asian Patients
Presenter: Dingwei Ye
Session: Poster Display session 3
Resources:
Abstract
2388 - Quality of Life of Metastatic Urothelial Cancer (mUC) Patients Treated with Enfortumab Vedotin (EV) Following Platinum-Containing Chemotherapy and a Checkpoint Inhibitor (CPI): Data from EV-201 Cohort 1
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
3748 - Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
1126 - Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors
Presenter: Rafael Morales Barrera
Session: Poster Display session 3
Resources:
Abstract
3693 - Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer
Presenter: Justin Matulay
Session: Poster Display session 3
Resources:
Abstract
4840 - Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
1221 - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
Presenter: Jean Hoffman-censits
Session: Poster Display session 3
Resources:
Abstract
1715 - National Small Cell Bladder Cancer Audit: Results from 26 UK institutions
Presenter: Caroline Chau
Session: Poster Display session 3
Resources:
Abstract